Overview

This book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that immunologists face in making further progress. MNT allows the creation of particles that exploit the inherent ability of the human immune system to recognize small particles such as viruses and toxins. In combination with minimal protective epitope design, this permits the creation of immunogenic particles that stimulate a response against the targeted pathogen. The finely tuned response of the human immune system to small particles makes it unsurprising that many of the lead adjuvants and vaccine delivery systems currently under investigation are based on nanoparticles.

Full Product Details

Author:   Mariusz Skwarczynski (Vice-Chancellor and Fellow, University of Queensland, Australia) ,  Istvan Toth (ARC Australian Professorial Fellow, Chair in Biological Chemistry, Professor of Pharmacy, Group Leader, IMB Division of Structural Biology)
Publisher:   Elsevier - Health Sciences Division
Imprint:   Elsevier - Health Sciences Division
Weight:   1.110kg
ISBN:  

9780323399814

ISBN 10:   0323399819
Pages:   460
Publication Date:   03 October 2016
Audience:   College/higher education ,  Professional and scholarly ,  Postgraduate, Research & Scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Overview of immune system. Innate immunity and special role of antigen presenting cells. Immunity and size. Introduction to the vaccines. Current challenges in vaccine development. Growing role of nanotechnology Nanotechnology in medical research Nanoparticle based peptide vaccines Liposome as nano- and microvaccines Lipid in peptide vaccine (excluding liposomes) Nanoadjuvants for peptide based vaccines Nanopatches for vaccine delivery Oral vaccine delivery Nano- and microtechnology in skin delivery of vaccines Nasal vaccine delivery Nanoparticles for cancer targeting vaccines by polymer based nanovaccines Lipidic microparticles for vaccine delivery Polymeric microparticles for vaccine delivery

Reviews

"""Overall, all the chapters uniquely illustrate various advantageous opportunities that micro- and nanotechnologies may contribute to the development of more precise and effective, as well as safe and economical vaccines without omitting risks and challenges that are still given today. Therefore, this book is a suitable reference for further research on vaccine development in a dawning era of nanotechnology in vaccination and immunotherapy."" --ChemMedChem"

Overall, all the chapters uniquely illustrate various advantageous opportunities that micro- and nanotechnologies may contribute to the development of more precise and effective, as well as safe and economical vaccines without omitting risks and challenges that are still given today. Therefore, this book is a suitable reference for further research on vaccine development in a dawning era of nanotechnology in vaccination and immunotherapy. --ChemMedChem

Author Information

Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology. His postdoctoral training began at Tokushima Bunri University under the direction of Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University to study prodrugs of paclitaxel. In 2004 he was awarded with prestigious Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem. In 2008 he joined Professor Istvan Toth group at University of Queensland to work on drug, gene and vaccine delivery strategies. Since then he research is mainly focused on nanotechnology-based vaccine delivery approaches. He has published over 60 peer-reviewed publications, 4 book chapters, and other 100 conference abstracts. Currently he is Vice-Chancellor Fellow at University of Queensland. Professor Toth is a chemical engineer with a research focus on medicinal chemistry. He was awarded his PhD in 1972 and has since worked in Hungary, Canada and the United Kingdom before relocating to Australia in 1998. His major research interests are drug delivery, immunoadjuvants, synthetic vaccines and gene delivery. His research has attracted over $60 million in competitive grants, research contracts and investment funds in the past 10 years. He has over 300 peer-reviewed publications, 43 patents, and an excellent track record in research commercialization as a key founder of Alchemia (ASX listed), Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development).

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions